Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico
Status:
Completed
Trial end date:
2015-10-07
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to report adverse events of on-treatment AEs by the
treating physicians during a specified 24-month study period in patients with venous
thromboembolism at the sentinel site(s) for the National Center of Pharmacovigilance (CNFV)
in Mexico.